Global DTaP and Tdap Vaccines Market Emerging Trends & Growing Popularity in upcoming year – Key Players involved in the research like Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp

Market Research Hub (MRH) has actively included a new research study titled “Global DTaP and Tdap Vaccines” Market Research Report 2019 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until forecast period limit; 2019. In addition, a deep analysis of the competitive landscape, including prime market players is also enclosed in this report.

Get Sample Copy of This Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2205727

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEFs total procurement.

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.

The global DTaP and Tdap Vaccines market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on DTaP and Tdap Vaccines volume and value at global level, regional level and company level. From a global perspective, this report represents overall DTaP and Tdap Vaccines market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc

Segment by Regions
North America
Europe
China
Japan

BROWSE Full Report NOW @ https://www.marketresearchhub.com/report/global-dtap-and-tdap-vaccines-market-research-report-2019-report.html

Table of Contents

Executive Summary
1 DTaP and Tdap Vaccines Market Overview
1.1 Product Overview and Scope of DTaP and Tdap Vaccines
1.2 DTaP and Tdap Vaccines Segment by Type
1.2.1 Global DTaP and Tdap Vaccines Production Growth Rate Comparison by Type (2014-2025)
1.2.2 DTaP
1.2.3 Td
1.2.4 Tdap
1.3 DTaP and Tdap Vaccines Segment by Application
1.3.1 DTaP and Tdap Vaccines Consumption Comparison by Application (2014-2025)
1.3.2 Adult
1.3.3 Pediatric
1.4 Global DTaP and Tdap Vaccines Market by Region
1.4.1 Global DTaP and Tdap Vaccines Market Size Region
1.4.2 North America Status and Prospect (2014-2025)
1.4.3 Europe Status and Prospect (2014-2025)
1.4.4 China Status and Prospect (2014-2025)
1.4.5 Japan Status and Prospect (2014-2025)
1.5 Global DTaP and Tdap Vaccines Market Size
1.5.1 Global DTaP and Tdap Vaccines Revenue (2014-2025)
1.5.2 Global DTaP and Tdap Vaccines Production (2014-2025)

2 Global DTaP and Tdap Vaccines Market Competition by Manufacturers
2.1 Global DTaP and Tdap Vaccines Production Market Share by Manufacturers (2014-2019)
2.2 Global DTaP and Tdap Vaccines Revenue Share by Manufacturers (2014-2019)
2.3 Global DTaP and Tdap Vaccines Average Price by Manufacturers (2014-2019)
2.4 Manufacturers DTaP and Tdap Vaccines Production Sites, Area Served, Product Types
2.5 DTaP and Tdap Vaccines Market Competitive Situation and Trends
2.5.1 DTaP and Tdap Vaccines Market Concentration Rate
2.5.2 DTaP and Tdap Vaccines Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global DTaP and Tdap Vaccines Production Market Share by Regions
3.1 Global DTaP and Tdap Vaccines Production Market Share by Regions
3.2 Global DTaP and Tdap Vaccines Revenue Market Share by Regions (2014-2019)
3.3 Global DTaP and Tdap Vaccines Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America DTaP and Tdap Vaccines Production
3.4.1 North America DTaP and Tdap Vaccines Production Growth Rate (2014-2019)
3.4.2 North America DTaP and Tdap Vaccines Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe DTaP and Tdap Vaccines Production
3.5.1 Europe DTaP and Tdap Vaccines Production Growth Rate (2014-2019)
3.5.2 Europe DTaP and Tdap Vaccines Production, Revenue, Price and Gross Margin (2014-2019)
3.6 China DTaP and Tdap Vaccines Production (2014-2019)
3.6.1 China DTaP and Tdap Vaccines Production Growth Rate (2014-2019)
3.6.2 China DTaP and Tdap Vaccines Production, Revenue, Price and Gross Margin (2014-2019)
3.7 Japan DTaP and Tdap Vaccines Production (2014-2019)
3.7.1 Japan DTaP and Tdap Vaccines Production Growth Rate (2014-2019)
3.7.2 Japan DTaP and Tdap Vaccines Production, Revenue, Price and Gross Margin (2014-2019)

4 Global DTaP and Tdap Vaccines Consumption by Regions
4.1 Global DTaP and Tdap Vaccines Consumption by Regions
4.2 North America DTaP and Tdap Vaccines Consumption (2014-2019)
4.3 Europe DTaP and Tdap Vaccines Consumption (2014-2019)
4.4 China DTaP and Tdap Vaccines Consumption (2014-2019)
4.5 Japan DTaP and Tdap Vaccines Consumption (2014-2019)

More Information………@@@

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com

This release was published on openPR.